ADAG

Rating neutralTentativeAI Memo

Adagene

As of 2026-10-14/Confidence low

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-14 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

neutral

Confidence

low

Horizon

—

Key catalyst

Randomized Phase 2 MSS colorectal cancer results • 2027-06-30

Base target: $2 / p=45% prob

Biggest risk

The value-defining randomized result remains pending. Earlier dose cohorts differed in response and Grade 3 adverse-event rates, so dose selection, trial execution, and eventual registration remain uncertain [#PR-EARNINGS-2026-08-12].

Invalidation

Break below $1 or thesis failure.

What would change my mind?

The reported $127.9 million June 2026 cash balance and company-expected runway into late 2028 provide time for the Phase 2 readout. Earlier muzastotug cohorts and additional pipeline activity offer upside if subsequent controlled data support efficacy and a tolerable regimen [#PR-EARNINGS-2026-08-12] [#PR-2026-09-22].

Research note

Recommendation

neutral

Confidence

low

As of

2026-10-14

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

ADG138 first-in-human study initiation
Dose selection and potential registration-trial transition
The reported $127.9 million June 2026 cash balance and company-expected runway into late 2028 provide time for the Phase 2 readout.

BearKey bullets

ADG138 has IND clearance but no human safety or efficacy results in the checked company announcement [#PR-2026-09-22].
Randomized Phase 2 efficacy may not reproduce the earlier nonrandomized cohort signals [#PR-EARNINGS-2026-08-12].
The higher-dose cohorts had a reported 38% Grade 3 treatment-related adverse-event rate, complicating dose selection [#PR-EARNINGS-2026-08-12].

WatchKey bullets

Randomized Phase 2 MSS colorectal cancer results

Summary

High-level snapshot

Recommendation

neutral

Model confidence

low

Timeframe

Asset

Equity

Trigger

Base case: $2 (p=45%)

Target spread vs base: +96% / -61%

Scenario probabilities

Bull Target: $5 (p=25%)Base Target: $2 (p=45%)Bear Target: $1 (p=30%)

Commentary

Cautious monitoring view. The company’s August results release and September ADG138 announcement establish identifiable clinical milestones, but neither resolves randomized efficacy. No reliable post-release price-reaction attribution, analyst revisions, or usable social, options, short-interest, and employee measures were supplied; zero-valued fields denote unavailable inputs, not neutral readings. The deterministic prior remains negative with 0.931 uncertainty and 0.08 evidence quality.

As of 2026-10-14 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

ADG138 first-in-human study initiation
Dose selection and potential registration-trial transition

Scenarios

Bull Target (Scenario probability)

$5 / p=25% prob

Base Target (Scenario probability)

$2 / p=45% prob

Bear Target (Scenario probability)

$1 / p=30% prob

Analysis 2026-10-14 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-06-30
Randomized Phase 2 MSS colorectal cancer results
Adagene expects results from its randomized muzastotug-plus-pembrolizumab dose-optimization study in 1H 2027. This is the principal efficacy and tolerability test: earlier nonrandomized cohorts showed different response rates by dose, while Grade 3 treatment-related adverse events were reported in 38% of patients in the 20 mg/kg cohorts [#PR-EARNINGS-2026-08-12]. Company release: https://investor.adagene.com/news-releases/news-release-details/adagene-reports-six-months-2026-financial-results-and-provides
Prob 52.00% • Move 50.00% • Priced-in 25.00%

Short-term Catalysts

Next few weeks

ADG138 first-in-human study initiation
2026-12-31
Following China’s clearance of the ADG138 investigational new drug application, Adagene expects to start a Phase 1 study in advanced solid tumors in Q4 2026. Starting the study would confirm execution, not clinical efficacy [#PR-2026-09-22]. Source: https://adagene.gcs-web.com/news-releases/news-release-details/adagene-announces-nmpa-clearance-investigational-new-drug/
Prob 65% • Move 10% • Priced-in 35%

Long-term Catalysts

Months to a year

Dose selection and potential registration-trial transition
2027-12-31
Adagene expects a potential registration trial in 2027 after establishing a recommended muzastotug dose regimen. Fast Track designation and reported FDA alignment support planning but do not establish that the randomized data will justify advancement [#PR-EARNINGS-2026-08-12]. Company release: https://investor.adagene.com/news-releases/news-release-details/adagene-reports-six-months-2026-financial-results-and-provides
Prob 40% • Move 25% • Priced-in 20%

Risks

ADG138 has IND clearance but no human safety or efficacy results in the checked company announcement [#PR-2026-09-22].
Randomized Phase 2 efficacy may not reproduce the earlier nonrandomized cohort signals [#PR-EARNINGS-2026-08-12].
The higher-dose cohorts had a reported 38% Grade 3 treatment-related adverse-event rate, complicating dose selection [#PR-EARNINGS-2026-08-12].
The late-2028 runway is a company expectation based on June 2026 cash, not a guarantee against future financing or dilution [#PR-EARNINGS-2026-08-12].

Peers

Symbol	Summary
DTIL	Loose same-sector, similar-market-cap biotechnology comparison from the supplied peer screen. Different development programs limit product-level valuation inference.
IPHA	Loose same-sector, similar-market-cap biotechnology comparison from the supplied peer screen; not established as a direct muzastotug or indication-level peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-14

Loading AI feed…

Symbol

Summary

DTIL

Loose same-sector, similar-market-cap biotechnology comparison from the supplied peer screen. Different development programs limit product-level valuation inference.

IPHA

Loose same-sector, similar-market-cap biotechnology comparison from the supplied peer screen; not established as a direct muzastotug or indication-level peer.